Healthcare Industry News: HemoSense
News Release - January 12, 2006
HemoSense Signs Agreement with ZyCare to Distribute INRatio and Utilize Web-Based Warfarin Patient Management SystemSAN JOSE, Calif.--(HSMN NewsFeed)--Jan. 12, 2006--HemoSense, Inc. (AMEX:HEM ) today announced that it has signed a marketing and distribution agreement with ZyCare, Inc. to integrate the use of HemoSense's INRatio® PT/INR Monitoring system with ZyCare's Web-based CoagCare® system for patient self-testing through physician practices and hospital clinics. INRatio is a portable Prothrombin Time/INR testing monitor, and CoagCare is the only FDA cleared, HIPAA compatible remote INR test reporting and dosage management system for patients on oral anticoagulant therapy.
CoagCare enables healthcare professionals to safely and cost-effectively monitor patients who use INRatio remotely at home. After performing a PT/INR test with INRatio, patients use a standard Internet browser to input INR test results into the CoagCare system. CoagCare then provides automated, patient specific warfarin dosage adjustments based on physician-prescribed algorithms. Test results are immediately available to healthcare providers, and patients who report out-of-range INR values or hemorrhagic or thromboembolic symptoms are prioritized for physician review.
"As a new distributor, ZyCare offers a unique benefit for our customers," said Timothy Still, executive vice president of sales and marketing for HemoSense. "CoagCare automates much of the reporting and data analysis required for dosing adjustments that are typically handled by a physician, thus enhancing the physician's ability to efficiently supervise patients using INRatio at home, while freeing their staff to focus on the patients who need the most attention."
Steve Holdaway, ZyCare's chief executive officer, added, "We believe that the combination of INRatio and CoagCare will provide a powerful solution to increase physician confidence both to prescribe and manage warfarin patients, while offering a high level of convenience for patients, who are free to travel and report their results from any location with Internet access."
INRatio and the CoagCare system will be available to home testing patients through ZyCare on March 1, 2006.
HemoSense develops, manufactures and markets easy-to-use, portable blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.HemoSense.com.
ZyCare develops medical information technology solutions that increase productivity for healthcare professionals in the management of chronic diseases while simultaneously improving quality of patient care and reducing costs. ZyCare utilizes innovative web-based "direct-to-patient expert systems"(TM) to automate much of the routine decision making involved in managing patients remotely. ZyCare's solutions directly involve patients in the information gathering that drives automated treatment recommendations, while giving physicians a vehicle to closely monitor their patient's progress without time consuming telephone calls and faxes. This approach allows the healthcare system to cost-effectively take advantage of new home monitoring devices for chronic conditions, while giving patients more control over their own condition. ZyCare's technology is protected by patents issued in the United States, Canada, Europe and Australia. For more information, visit www.zycare.com.
HemoSense® and INRatio® are registered trademarks of HemoSense, Inc.
CoagCare® is a registered trademark of ZyCare, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.